SNAP-8
Description
SNAP-8, also known as Acetyl Octapeptide-3, represents an evolution in cosmetic peptide technology. Developed as an extension of the popular hexapeptide Argireline, SNAP-8 contains two additional amino acids that enhance its ability to modulate neuromuscular junction activity. The peptide works by competing with SNAP-25 (Synaptosomal-Associated Protein of 25 kDa) for positions in the SNARE complex—the molecular machinery responsible for neurotransmitter release that triggers muscle contraction. By partially inhibiting this process, SNAP-8 can reduce the intensity of facial muscle movements that create expression lines over time. Unlike neurotoxin injections, SNAP-8 produces gradual, moderate effects through topical application, making it a popular ingredient in anti-aging skincare formulations marketed as 'botox alternatives.'
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[8].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days for maximum potency[8].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if needed.
How It Works
SNAP-8 is an extended analog of Argireline (hexapeptide) designed to mimic the SNAP-25 protein, which plays a crucial role in neurotransmitter release[1][2]. By competitively inhibiting SNAP-25 in the SNARE complex, SNAP-8 reduces acetylcholine release at neuromuscular junctions, leading to gentle muscle relaxation[5]. Unlike botulinum toxin (Botox) which cleaves SNAP-25 and causes muscle paralysis, SNAP-8 provides a milder, non-paralyzing effect that preserves natural facial expressions while reducing the depth of expression lines[1][5]. Preclinical studies showed SNAP-8 demonstrated approximately 30% greater activity than Argireline in reducing neurotransmitter release, with enhanced formulation stability[5].
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Reduces wrinkle depth by an average of approximately 35%, with maximal improvements approaching 60% in certain areas after 28–30 days of consistent application in topical studies[5].
- A 24-subject clinical trial using dissolving microneedle patches containing SNAP-8 showed significant reduction in eye wrinkles and improved skin elasticity over 4 weeks, with no adverse effects reported[4].
- An open-label 14-week study of a multi-peptide serum including SNAP-8 noted statistically significant smoothing of expression lines with good tolerability and no serious side effects[3].
- Generally well tolerated; occasional mild injection-site reactions (temporary redness, swelling, or soreness) may occur with subcutaneous administration[6].
- No systemic toxicity observed at typical doses; no reports of unwanted muscle weakness or systemic effects[5].
References
-
International Journal of Cosmetic ScienceArgireline hexapeptide with antiwrinkle activity (human study; 10% cream reduced wrinkle depth ~30% after 30 days)
-
Journal of Analytical Science and TechnologyMethod development for acetyl octapeptide-3 (SNAP-8) analysis by LC-MS/MS; stability and analytical characterization
-
Journal of Drugs in DermatologyOpen-label 14-week trial of multi-peptide serum (including SNAP-8); statistically significant smoothing of expression lines with good tolerability
-
Annals of DermatologyClinical safety and efficacy evaluation of dissolving microneedle patch containing SNAP-8; 24-subject trial showed significant wrinkle reduction and improved elasticity over 4 weeks with no adverse effects
-
Frontiers in ChemistryCosmeceutical peptides review; SNAP-8 mechanism (SNARE complex inhibition), ~30% greater activity than Argireline, and enhanced stability
-
Advances in TherapySubcutaneous injection of drugs: literature review of factors influencing pain sensation; fine gauge needles and small volumes minimize discomfort
-
MedlinePlus (NLM/NIH)Subcutaneous injection patient instructions; technique, site selection, and rotation guidance
-
GenScript Technical ResourcesPeptide storage and handling guidelines; lyophilized storage at −20 °C, reconstituted refrigeration, and stability considerations
-
CDCVaccine administration: subcutaneous route guidance (angle, site, and technique)
-
CDC (Subcut Injection PDF)Technique diagram and site guidance for subcutaneous injections
-
NCBI BookshelfBest practices for injection technique (asepsis, preparation, administration, and site rotation)
Certificate of Analysis
Every batch of SNAP-8 is independently lab-tested to a minimum of 98% purity. A Certificate of Analysis is available on request — contact us with your order or lot number and we'll send the COA for your specific batch.
Request a COAResearch Protocol
Full dose-by-dose reconstitution & dosing protocol for SNAP-8.
View Research Protocol →Research protocol for this size is coming soon.
For laboratory and scientific research use only. Not medical advice.
For laboratory and research use only. Minimum 98% purity. Supplied in sterile, flip-top headspace vials for laboratory use. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. The purchaser accepts full responsibility for safe handling, storage and lawful use.
